Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Marie Skłodowska-Curie Action · Finished

MossTOR Investigating the TORC1 signaling pathway in the moss Physcomitrella and its application for enhanced production of valuable pharmaceutical compounds

Coordinator
Albert-Ludwigs-Universitaet Freiburg, Germany
Runs
1 August 2022 to 31 August 2025
Status
Finished
EU funding
€237k
Total cost
—
Partners
3 organisations in 2 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101065000

What the project is doing

In the project's own words, from its summary on CORDIS.

The Target of Rapamycin Complex 1 (TORC1) signaling pathway, involved in the coordination of cell growth and metabolism, is highly conserved among eukaryotes, including seed plants and algae. Studies have shown that its activity could be tuned to enhance plant growth, yield and resistance to stress, or accumulation of triacylglycerol in algae, thus indicating that its power could be harnessed to improve diverse plant biotechnological applications.

In this project, I aim to characterize the TORC1 pathway for the first time in the moss Physcomitrella (Physcomitrium patens), a model organism of non-seed plants, using protonema cells as a study system. This is linked to another important goal, to test whether the activity of TORC1 can be modulated in order to improve moss-based biotechnological applications. Besides the identification of a functional TORC1 in Physcomitrella, I will develop transgenic lines with hyperactive TORC1 signaling, phenotypically and metabolically analyzing them, and in collaboration with Mosspiration Biotech, test if these lines could produce more human recombinant complement proteins or the drug artemisinin, used to treat patients with complement disorders or malaria, respectively.

Enhancing this yield will result in a stable, sustainable and eco-friendly production platform. It would also lead to a reduced price, for instance of artemisinin-based treatments, thus allowing poor communities most affected by malaria to contain the disease. Should this project be successful, it will open the door to improve the yield of diverse well-established products from Physcomitrella, valuable metabolites, active pharmaceutical ingredients and biopharmaceutical proteins.

Who is involved

OrganisationCityCountryRole
Albert-Ludwigs-Universitaet FreiburgFreiburgGermanyCoordinator
Mosspiration Biotech ApsGlostrupDenmarkAssociatedpartner
Tailwind Biotech ApSCopenhagenDenmarkAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI